Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05580042 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
A Phase 1 study, sponsored by TWi Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05580042 is a Phase 1 study that has completed, run by TWi Biotechnology. The registered enrollment target is 13 participants.
The verdict
NCT05580042, a Phase 1 study, has completed, sponsored by TWi Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Study AC-1101-GA-001 is an early phase open-label study with a 4-week treatment and 2-week follow-up period (without treatment) to assess the safety, tolerability, and efficacy of AC-1101 gel in patients with Granuloma Annulare.
Interventions
- DRUG AC-1101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2023-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05580042
The ClinicalTrials.gov registry entry for NCT05580042 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TWi Biotechnology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AC-1101 is the first listed.
NCT05580042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05580042 about?
NCT05580042 is a clinical study titled "Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare". Study AC-1101-GA-001 is an early phase open-label study with a 4-week treatment and 2-week follow-up period (without treatment) to assess the safety, tolerability, and efficacy of AC-1101 gel in patients with Granuloma Annulare.
What is the current status of trial NCT05580042?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2022-10-03. Estimated completion is 2023-11-15.
What interventions are being tested in trial NCT05580042?
The interventions under investigation include: AC-1101 (DRUG).
Who is sponsoring clinical trial NCT05580042?
This trial is sponsored by TWi Biotechnology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.